Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED BALANCE SHEETS (unaudited)

v2.4.0.8
CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)
Sep. 30, 2013
Dec. 31, 2012
ASSETS    
Cash $ 837 $ 782
Total current assets 837 782
Fixed assets - net 1,425 1,496
Patents & Trademarks 1,000   
Total Assets 3,262 2,278
LIABILITIES & STOCKHOLDERS' EQUITY    
Accounts payable 459,607 298,994
Accrued interest payable 156,348 159,355
Notes payable - current - related parties 703,516 390,915
Notes payable - current 480,398 225,136
Note discount (29,164) (38,072)
Notes payable - equity obligation payable 447,602 463,037
Stock subscription payable - current 26,000 26,000
Related party payables 360,424 351,310
Other payables    158,006
Total current liabilities 2,604,731 2,034,681
Notes payable - related parties 167,007 363,888
Total Liabilities 2,771,738 2,398,569
Stockholders' Equity    
Common stock, $.00001 par value;100,000,000 shares authorized;34,146,712 and 30,315,554 shares issued and outstanding at September 30, 2013 and December 31, 2012 respectively 342 303
Additional paid in capital 12,380,124 11,903,279
Deficit accumulated during the development stage (15,118,407) (14,274,244)
Total TransBiotec, Inc. stockholders' equity (2,737,941) (2,370,662)
Noncontrolling interest (30,535) (25,629)
Total Stockholders' Equity (2,768,476) (2,396,291)
Total Liabilities and Stockholders' Equity $ 3,262 $ 2,278